Recent Updates
Recently added Catalysts

LBL-007

Phase 3

Esophageal Cancer | Small Molecules | Oncology |BeOne Medicines Ltd.|Trials Updated: Jul 23, 2026

LBL-007 development status

Highest phase Phase 3 (NCT04164199)
Phase scored for ONCPhase 2
Registered trials 7 across 2 sponsors since Nov 2018

LBL-007 target and mechanism

Molecular targetLAG-3
Target classProtein
ModalitySmall Molecules

Also known as Alcestobart

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials2
Total Enrollment231

FDA Designations

No designations recorded

LBL-007 clinical trials

LBL-007 · 2 trials · 4 indications

Phase 2 1Phase 1/2 1
NCT06010303A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaEsophageal Cancer
COMPLETED118 Analytics
PHASE2COMPLETED
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Overall Response Rate (ORR)
Approximately 10 months

Percentage of participants whose best overall response (BOR) is complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.

Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)
From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C
From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)

PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.

Secondary Endpoints

Progression Free Survival (PFS)
Approximately 18 months
Duration of Response (DOR)
Approximately 18 months
Disease Control Rate (DCR)
Approximately 18 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LBL-007EXPERIMENTALLBL-007 in combination with tislelizumab plus chemotherapy doublet.
Tislelizumab and ChemotherapyACTIVE_COMPARATORTislelizumab plus chemotherapy doublet.
Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidineEXPERIMENTALParticipants received alcestobart low dose, tislelizumab, bevacizumab and capecitabine until disease progression, unacceptable toxicity, or withdrawal of consent.
Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidineEXPERIMENTALParticipants received alcestobart medium dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidineEXPERIMENTALParticipants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 2: Arm A:PD-L1-positive: Alcestobart High Dose +Tislelizumab + Bevacizumab +FluoropyrimidineEXPERIMENTALPD-L1 (programmed cell death protein ligand-1)-positive participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidineEXPERIMENTALPD-L1-positive participants received alcestobart high dose, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidineACTIVE_COMPARATORPD-L1-positive participants received bevacizumab and fluoropyrimidine in combination with leucovorin or levoleucovorin (LV) until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ FluoropyrimidineEXPERIMENTALPD-L1-negative participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).
Phase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineACTIVE_COMPARATORPD-L1-negative participants received bevacizumab and fluoropyrimidine in combination with LV until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

Interventions

NameTypeDescription
LBL-007DRUGLBL-007 will be administered at a standard dose intravenously.
TislelizumabDRUGTislelizumab will be administered at a standard dose intravenously.
Chemotherapy DoubletDRUGDoublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
AlcestobartDRUGAdministered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks
Bevacizumab or Bevacizumab biosimilarDRUGAdministered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks.
Fluoropyrimidine (FP)DRUGFluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites38

Inclusion Criteria: * Able to provide written informed consent and can agree to comply with the study requirements. * Participants with metastatic ESCC or unresectable, locally advanced ESCC. * Histologically confirmed diagnosis of ESCC. * Can provide a tumor sample. * At least 1 measurable lesion ...

Countries:ChinaSouth KoreaTaiwanThailandUnited StatesAustraliaPuerto Rico
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMNov 10, 2026NCT05609370lastUpdatePostDate: changed

Frequently asked questions about LBL-007

What is LBL-007?

LBL-007 is an investigational small molecule developed by BeOne Medicines Ltd. (ticker ONC). It is being studied in oncology as a LAG-3 targeted agent, both in esophageal cancer and in unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer. It is currently in Phase 2 clinical development.

What is LBL-007 used for?

LBL-007 is being evaluated for the treatment of esophageal cancer, including esophageal squamous cell carcinoma, and for unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer. It is an investigational therapy and is not approved for any indication.

What does LBL-007 target?

LBL-007 targets LAG-3, a protein immune checkpoint receptor. By binding LAG-3, the drug is designed to modulate an inhibitory pathway that suppresses T cell activity. In clinical studies it is given in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy or bevacizumab plus fluoropyrimidine.

Who makes LBL-007?

LBL-007 is developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company is running the clinical program for the asset across sites in China, South Korea, Taiwan, Thailand, the United States, Australia, and Puerto Rico.

What phase is LBL-007 in?

LBL-007 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The Phase 2 study in esophageal squamous cell carcinoma has completed, while a Phase 1 colorectal cancer study remains active but is no longer recruiting.

What clinical trials is LBL-007 in?

LBL-007 has been studied in two registered trials. NCT06010303 is a completed Phase 2 study of LBL-007 plus tislelizumab and chemotherapy in unresectable locally advanced or metastatic esophageal squamous cell carcinoma, enrolling 118 participants. NCT05609370 is an active Phase 1 study in unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer, enrolling 113 participants.